Home
About Us
Our Science
News and Events
Careers
Contact
Select Page
Oral ALX-001 Achieves Full Brain Receptor Occupancy
by
Tim Siegert
|
Oct 30, 2023
|
Press Release
ALX-001 Phase 1 Presentation at CTAD
by
Tim Siegert
|
Oct 19, 2023
|
Press Release
Search
Search
Recent Posts
Yale’s Adam Mecca, MD, PhD Discusses ALX-001 with NeurologyLive
Allyx sets Phase II plans for AD in motion after Phase Ia
Oral ALX-001 Achieves Full Brain Receptor Occupancy
ALX-001 Phase 1 Presentation at CTAD
NIA Small Business Showcase: Allyx Therapeutics, Inc.
